Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 5/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.59 |
| ▸ | HTR2B | P41595 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407324 | 1.00 | HRH4 (0.65) | HRH4DRD2CHRM1DRD3LMNA | |
| SCHEMBL144624 | 0.87 | DRD2 (0.74) | HRH4DRD2CHRM1DRD3LMNA | |
| SCHEMBL7413950 | 0.80 | HRH4 (0.71) | HRH4DRD2CHRM1DRD3LMNA | |
| SCHEMBL8022151 | 0.79 | DRD2 (0.80) | HRH4DRD2CHRM1DRD3LMNA | |
| SCHEMBL13409925 | 0.79 | HRH4 (0.74) | HRH4DRD2CHRM1DRD3LMNA | |
| SCHEMBL29384841 | 0.78 | HRH4 (0.59) | HRH4DRD2CHRM1DRD3LMNA | |
| SCHEMBL9181334 | 0.78 | HRH4 (0.59) | HRH4DRD2CHRM1DRD3LMNA | |
| Metiapine SCHEMBL29710898 | 0.75 | DRD2 (0.76) | HRH4DRD2CHRM1DRD3LMNA | |
| Metiapine SCHEMBL121263 | 0.75 | DRD2 (0.76) | HRH4DRD2CHRM1DRD3LMNA | |
| SCHEMBL11559143 | 0.75 | DRD2 (0.59) | HRH4DRD2CHRM1DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0607129-B1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH SA (BE) | 1995-08-23 | — | — | EP | claimed |
| US-5393752-A | Psycholigical disorders | THERABEL RESEARCH S.A./N.V. (BE) | 1995-02-28 | — | — | US | claimed |
| EP-0607129-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE. | THERABEL RESEARCH SA (BE) | 1994-07-27 | — | — | EP | claimed |
| WO-1993007143-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH S.A./N.V. (BE) | 1993-04-15 | — | — | WO | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2010048264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090075951-A1 | Methods and Reagents for the Treatment of Inflammatory Disorders | COMBINATORX, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0607129-B1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH SA (BE) | 1995-08-23 | — | — | EP | disclosed |
| US-5393752-A | Psycholigical disorders | THERABEL RESEARCH S.A./N.V. (BE) | 1995-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | HRH4 171/4885DRD2 59/4885CHRM1 1417/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | HRH4 675/4885DRD2 3053/4885CHRM1 3915/4885 |
| US-20090075951-A1 | Methods and Reagents for the Treatment of Inflammatory Disorders | IL5, TNF, LTC4S | HRH4 159/4885DRD2 3820/4885CHRM1 3454/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | HRH4 354/4885DRD2 4506/4885CHRM1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.